{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:01:54Z","timestamp":1780761714444,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Carbohydrate antigen 19-9 (CA19-9) represents an established prognostic biomarker for biliary tract cancers (BTCs). Clinical utility remains limited among patients with Lewis antigen negativity or incomplete fucosyltransferase 3 (\n                      <jats:italic>FUT3<\/jats:italic>\n                      ) gene function, conditions associated with absent or reduced CA19-9 production. Duke pancreatic monoclonal antigen type 2 (DUPAN-2), a biosynthetic precursor of CA19-9, shows compensatory elevation under such conditions. This study evaluated the prognostic significance of the combined preoperative assessment of CA19-9 and DUPAN-2 among patients with resectable BTCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients who underwent curative-intent surgery for BTCs between 2009 and 2022 were included. Eligible patients were classified into four groups according to preoperative biomarker levels: normal CA19-9\/normal DUPAN-2 (N\/N), normal CA19-9\/high DUPAN-2 (N\/H), high CA19-9\/normal DUPAN-2 (H\/N), and high CA19-9\/high DUPAN-2 (H\/H). Clinicopathological features, overall survival (OS), and recurrence-free survival (RFS) were compared. Multivariate analyses identified independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included 276 patients with BTCs who underwent curative resection, comprising 41 intrahepatic cholangiocarcinomas, 72 hilar cholangiocarcinomas, 57 distal cholangiocarcinomas, 53 gallbladder carcinomas, and 53 ampullary carcinomas. Age and tumor distribution showed no significant intergroup differences. The N\/N group demonstrated significantly superior OS and RFS (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Multivariate analysis identified the N\/N profile as an independent favorable prognostic factor for OS and RFS (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Concurrent normal CA19-9 and DUPAN-2 levels independently predicted favorable outcomes. Combined preoperative biomarker assessment may contribute to prognostic stratification of BTCs, including among patients with Lewis antigen negativity or impaired FUT3 function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19488-2","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:51:36Z","timestamp":1774536696000},"page":"6041-6049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Combined Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Ryuta","family":"Shintakuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-6268","authenticated-orcid":false,"given":"Kenichiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Tazuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"19488_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/bjs.10415","volume":"104","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Passot G, Aloia TA, et al. Prognostic value of carbohydrate antigen 19\u20139 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017;104:267\u201377.","journal-title":"Br J Surg."},{"key":"19488_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/jso.23666","volume":"110","author":"N Kondo","year":"2014","unstructured":"Kondo N, Murakami Y, Uemura K, et al. Elevated perioperative serum CA 19\u20139 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014;110:422\u20139.","journal-title":"J Surg Oncol."},{"key":"19488_CR3","first-page":"5501","volume":"47","author":"MA Tempero","year":"1987","unstructured":"Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19\u20139 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501\u20133.","journal-title":"Cancer Res."},{"key":"19488_CR4","doi-asserted-by":"publisher","first-page":"32260","DOI":"10.1074\/jbc.271.50.32260","volume":"271","author":"TF Orntoft","year":"1996","unstructured":"Orntoft TF, Vestergaard EM, Holmes E, et al. Influence of Lewis alpha1-3\/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. J Biol Chem. 1996;271:32260\u20138.","journal-title":"J Biol Chem."},{"key":"19488_CR5","first-page":"512","volume":"58","author":"H Narimatsu","year":"1998","unstructured":"Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DUPAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512\u20138.","journal-title":"Cancer Res."},{"key":"19488_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.cgh.2019.10.036","volume":"18","author":"T Abe","year":"2020","unstructured":"Abe T, Koi C, Kohi S, et al. Gene variants that affect levels of circulating tumor markers increase identification of patients with pancreatic cancer. Clin Gastroenterol Hepatol. 2020;18:1161-1169.e5.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"19488_CR7","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1200\/JCO.23.01573","volume":"42","author":"Y Ando","year":"2024","unstructured":"Ando Y, Dbouk M, Yoshida T, et al. Using tumor marker gene variants to improve the diagnostic accuracy of DUPAN-2 and carbohydrate antigen 19\u20139 for pancreatic cancer. J Clin Oncol. 2024;42:2196\u2013206.","journal-title":"J Clin Oncol."},{"key":"19488_CR8","doi-asserted-by":"publisher","first-page":"e1278","DOI":"10.1097\/SLA.0000000000005395","volume":"277","author":"K Omiya","year":"2023","unstructured":"Omiya K, Oba A, Inoue Y, et al. Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer. Ann Surg. 2023;277:e1278\u201383.","journal-title":"Ann Surg."},{"key":"19488_CR9","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1245\/s10434-023-13564-7","volume":"30","author":"Y Shimizu","year":"2023","unstructured":"Shimizu Y, Sugiura T, Ashida R, et al. Prognostic role of preoperative Duke pancreatic monoclonal antigen type 2 levels in patients with pancreatic cancer. Ann Surg Oncol. 2023;30:5792\u2013800.","journal-title":"Ann Surg Oncol."},{"key":"19488_CR10","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1245\/s10434-024-15221-z","volume":"31","author":"T Sumiyoshi","year":"2024","unstructured":"Sumiyoshi T, Uemura K, Shintakuya R, et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. Ann Surg Oncol. 2024;31:4665\u201372.","journal-title":"Ann Surg Oncol."},{"key":"19488_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg."},{"key":"19488_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s10147-022-02165-1","volume":"27","author":"R Hamura","year":"2022","unstructured":"Hamura R, Haruki K, Taniai T, et al. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis. Int J Clin Oncol. 2022;27:1188\u201395.","journal-title":"Int J Clin Oncol."},{"key":"19488_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","volume":"258","author":"M Nagino","year":"2013","unstructured":"Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129\u201340.","journal-title":"Ann Surg."},{"key":"19488_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/annonc\/mdw063","volume":"27","author":"B Groot Koerkamp","year":"2016","unstructured":"Groot Koerkamp B, Wiggers JK, Gonen M, et al. Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. Ann Oncol. 2016;27:753.","journal-title":"Ann Oncol."},{"key":"19488_CR15","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1245\/s10434-022-11931-4","volume":"29","author":"I Hosokawa","year":"2022","unstructured":"Hosokawa I, Hayano K, Furukawa K, et al. Preoperative diagnosis of lymph node metastasis of perihilar cholangiocarcinoma using diffusion-weighted magnetic resonance imaging. Ann Surg Oncol. 2022;29:5502\u201310.","journal-title":"Ann Surg Oncol."},{"key":"19488_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jhbp.552","volume":"25","author":"T Yoh","year":"2018","unstructured":"Yoh T, Hatano E, Seo S, et al. Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2018;25:299\u2013307.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"19488_CR17","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1245\/s10434-022-12028-8","volume":"29","author":"S Zhang","year":"2022","unstructured":"Zhang S, Huang S, He W, et al. Radiomics-based preoperative prediction of lymph node metastasis in intrahepatic cholangiocarcinoma using contrast-enhanced computed tomography. Ann Surg Oncol. 2022;29:6786\u201399.","journal-title":"Ann Surg Oncol."},{"key":"19488_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jso.21811","volume":"103","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Nagano H, Hoshino H, et al. Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer. J Surg Oncol. 2011;103:223\u20139.","journal-title":"J Surg Oncol."},{"key":"19488_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12885-021-08204-w","volume":"21","author":"B Zhao","year":"2021","unstructured":"Zhao B, Cheng Q, Cao H, et al. Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas. BMC Cancer. 2021;21:517.","journal-title":"BMC Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19488-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:52:18Z","timestamp":1780761138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19488"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19488-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}